RISEDRONATE SANDOZ 35 mg, film-coated tablet 4 tablets
Active ingredients: Risedronic acid, Risedronate sodium hemi-pentahydrate
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet4 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- RISEDRONATE SANDOZ 35 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) aluminium PVC de 4 comprimé(s)
- Marketing authorisation holder
- SANDOZ
- Reimbursement according to BDPM
- 65%
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- Réduction du risque de fractures vertébrales et de hanche, chez les patientes atteintes d'ostéoporose postménopausique répondant à certains critères cliniques de gravité <br>- Ostéoporose masculine. ; JOURNAL OFFICIEL ; 27/06/03
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 16 Dec 2010
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64260929CIP74945708CIP133400949457083Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RISÉDRONATE MONOSODIQUEcomprimé | 35 mg · un comprimé | SA |
| ACIDE RISÉDRONIQUEcomprimé | 32,5 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.